Overview

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
AG-013,958 is being studied to treat patients with Age-Related Macular Degeneration. A total of 144 subjects may be enrolled in the trial. Subjects will be male or female at least 55 years of age with "wet" age-related macular degeneration.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Pfizer